Six patients were imaged for primary staging of prostate cancer, 17 patients for biochemical recurrence, 36 patients for (biochemical) progression, and 33 patients were evaluated prior to [177Lu]Lu-PSMA-617 therapy or [223Ra]Ra-dichloride therapy. This evidence concerns the gene FOLH1 and prostate carcinoma.